In vitro activation of the CB 1 receptor by the semi‐synthetic cannabinoids hexahydrocannabinol (HHC), hexahydrocannabinol acetate (HHC‐O) and hexahydrocannabiphorol (HHC‐P)
Drug Testing and Analysis · 2025-04 · 17 (4) · 487-493
DOI: 10.1002/dta.3750 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, online erschienen am 19.06.2024. Verfasst von Mattias Persson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping, Sweden. Hauptthemen laut MEDLINE: Receptor, Cannabinoid, CB1, Cannabinoids, Dronabinol, Cannabinoid Receptor Agonists. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Monitoring Centre for Drugs and Drug Addiction, Public Health Agency of Sweden, Folkhälsomyndigheten.
Abstract (Originalsprache)
Semi‐synthetic cannabinoids (SSCs) including hexahydrocannabinol (HHC) are emerging on the drug market and sold openly as purportedly legal replacements for cannabis and Δ 9 ‐THC. By the beginning of 2024, 24 European countries had identified HHC, often sold openly in edibles (foods/candy), vapes and low‐THC cannabis flowers and resins. The SSC market is developing rapidly, with HHC acetate (HHC‐O), hexahydrocannabiphorol (HHC‐P) and others recently identified. These developments may mark the first major change in the market for ‘legal’ replacements to cannabis since ‘Spice’ containing synthetic cannabinoids, such as JWH‐018, emerged in 2008. Currently, there are some data available on the pharmacology of SSCs, which is crucial for understanding their effects, evaluating health risks and informing public health responses. This study focused on characterizing the in vitro activation of the human CB 1 receptor by the ( R ) ‐ and ( S ) ‐ epimers of HHC, HHC‐P and HHC‐O. Using recombinant CHO‐K1 cells expressing the human CB 1 receptor, the potency (EC 50 ) and efficacy were determined. It was established that (9 R )‐HHC and (9 R )‐HHC‐P activated the CB 1 receptor as partial agonists and with five and two times lower potency compared to JWH‐018, respectively, while the ( S ) ‐ epimers exhibited even lower potency. The ( R ) ‐ epimer of HHC‐O activate the CB 1 receptor to even lesser extent and the ( S )‐epimer showed no activation. For HHC and HHC‐P, all epimers exhibited similar level of efficacy. This available evidence suggests cannabimimetic effects of the tested SSC with the exception for the acetates that likely function as pro‐drugs in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping, Sweden.
- Division of Clinical Chemistry and Pharmacology, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
- European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal.
ORCID-Profile: Mattias Persson, Robert Kronstrand, Michael Evans-Brown, Henrik Green
Förderung
- European Monitoring Centre for Drugs and Drug Addiction
- Public Health Agency of Sweden
- Folkhälsomyndigheten
Zitieren
APA
Persson, M., Kronstrand, R., Evans-Brown, M., & Green, H. (2025). In vitro activation of the CB 1 receptor by the semi‐synthetic cannabinoids hexahydrocannabinol (HHC), hexahydrocannabinol acetate (HHC‐O) and hexahydrocannabiphorol (HHC‐P). Drug Testing and Analysis, 17(4), 487-493. https://doi.org/10.1002/dta.3750
Vancouver
Persson M, Kronstrand R, Evans-Brown M, Green H. In vitro activation of the CB 1 receptor by the semi‐synthetic cannabinoids hexahydrocannabinol (HHC), hexahydrocannabinol acetate (HHC‐O) and hexahydrocannabiphorol (HHC‐P). Drug Testing and Analysis. 2025;17(4):487-493. doi:10.1002/dta.3750
BibTeX
@article{Persson2025,
author = {Persson, Mattias and Kronstrand, Robert and Evans-Brown, Michael and Green, Henrik},
title = {In vitro activation of the CB 1 receptor by the semi‐synthetic cannabinoids hexahydrocannabinol (HHC), hexahydrocannabinol acetate (HHC‐O) and hexahydrocannabiphorol (HHC‐P)},
journal = {Drug Testing and Analysis},
year = {2025},
volume = {17},
number = {4},
pages = {487--493},
doi = {10.1002/dta.3750}
}
EUVIMED